Demonstrates noninferior cardiovascular safety and hemoglobin control with vadadustat versus darbepoetin alfa in dialysis patients, supporting an oral therapy option.
Among patients with anemia and CKD who were undergoing dialysis, vadadustat was noninferior to darbepoetin alfa with respect to cardiovascular safety and correction and maintenance of hemoglobin concentrations. (Funded by Akebia Therapeutics and Otsuka Pharmaceutical; INNO₂VATE ClinicalTrials.gov numbers, NCT02865850 and NCT02892149.).
No takes yet. Share an insight, caveat, or question.
Eckardt et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: